Earnings Ahead

APVO - Aptevo Therapeutics

1.39 0.05 3.73

Aptevo Therapeutics

Aptevo Therapeutics

About

Profile


Headquarters

Seattle, Washington, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

APVO



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Aptevo Therapeutics GAAP EPS of $1.57 beats by $0.64, revenue of $3.11M in-line
  • Aptevo Therapeutics raises $9.6M in non-dilutive funding
  • Aptevo shares more than double in value on phase 1 data for its leukemia drug candidate
  • Aptevo Therapeutics GAAP EPS of -$1.50 beats by $0.14
  • Aptevo Therapeutics receives approval to begin human trial of solid tumor therapy
  • Aptevo Therapeutics GAAP EPS of $5.58
  • Aptevo gains after disclosing additional remission data in leukemia trial
  • Aptevo Therapeutics GAAP EPS of -$1.59 misses by $0.66, revenue of $3.11M misses by $0.64M
  • Aptevo climbs as 2021 revenue more than doubles
  • Aptevo Therapeutics GAAP EPS of -$6.07 beats by $0.07, revenue of $12.29M beats by $0.26M
  • Aptevo Therapeutics receives $10M in non-dilutive milestone payment on RUXIENCE sales
  • Aptevo Therapeutics Board Chairman Fuad El-Hibri to retire
  • Aptevo stock nearly doubles after APVO436 + chemotherapy resulted in complete remission in AML
  • Aptevo Therapeutics EPS beats by $0.03, misses on revenue
  • Aptevo reports research on APVO436 for cytokine release syndrome in cancer patients
  • Aptevo reports APVO436 monotherapy results in blood cancers in oncology journal
  • Aptevo Therapeutics EPS beats by $0.06, beats on revenue
  • China SXT Pharmaceuticals, Trinity Biotech leads healthcare gainers; FibroGen, Neptune Wellness Solutions among major losers
  • Aptevo Therapeutics added to the Russell Microcap Index
  • Aptevo initiates expansion phase of APVO436 acute myeloid leukemia study
PEERS

Earnings History

Date EPS / Forecast Revenue / Forecast
November 12, 2021 -1.45 / -1.43 3.1M / 3.1M
August 13, 2021 -1.78 / -2 3.11M / 1.35M Beat!
August 12, 2021 -2.1 / -2 1.35M / 900K
May 11, 2021 -1.74 / -1.67 2.42M / 2.42M Beat!
March 31, 2021 -1.81 / -1.51 2.37M / 1.74M Beat!
November 11, 2020 -2.15 / -2.05 1.5M / 1.48M Beat!
August 17, 2020 - / -2.12 - / 105K
May 13, 2020 -3.06 / -2.35 - / 5.17M Beat!
March 30, 2020 -0.2 / -0.23 9.03M / 9.87M
November 7, 2019 -0.23 / -0.31 9.01M / 8.37M Beat!
August 9, 2019 -0.3 / -0.33 7.36M / 7.04M Beat!
May 9, 2019 -0.44 / -0.44 7.02M / 6.77M Beat!
March 18, 2019 -0.62 / -0.53 6.35M / 6.28M Beat!
November 14, 2018 -0.56 / -0.57 5.82M / 6.93M
August 9, 2018 -0.58 / -0.65 6.83M / 4.17M Beat!
March 29, 2018 - / -0.32 - / 3.00M
June 30, 2017 - / 2.25 7.41M / - Beat!
March 27, 2017 0.01 / -0.48 8.77M / - Beat!
November 24, 2016 -0.79 / -0.44 9.41M / - Beat!
Date Price Open High Low Vol Change ER
Jun 8 5.68 5.57
5.68
5.14
19.95K 2.90%
Jun 7 5.52 5.17
6.14
5.07
106.77K 7.18%
Jun 6 5.15 4.83
5.17
4.83
16.69K 3.21%
Jun 3 4.99 4.72
4.99
4.66
16.25K 5.72%
Jun 2 4.72 4.74
4.74
4.50
6.16K 4.42%
 
Jun 1 4.52 4.59
4.68
4.51
9.97K -1.31%
May 31 4.58 4.70
4.84
4.58
10.41K -6.15%
May 27 4.88 4.67
4.97
4.55
38.82K 3.83%
May 26 4.70 4.75
5.28
4.59
79.25K -2.89%
May 25 4.84 4.75
4.84
4.67
11.15K 1.89%
May 24 4.75 4.70
4.81
4.48
18.35K -1.66%
May 23 4.83 4.56
4.95
4.47
45.30K 6.15%
May 20 4.55 4.88
4.88
4.33
23.75K -5.8%
May 19 4.83 4.67
4.87
4.63
9.47K 3.21%
May 18 4.68 4.67
4.88
4.58
11.11K -3.31%
May 17 4.84 4.72
4.84
4.50
23.02K 4.54%
May 16 4.63 4.62
4.79
4.47
23.99K 0.65%
May 13 4.60 4.40
4.60
4.21
53.29K 8.24%
May 12 4.25 3.45
4.36
3.45
81.42K 11.26%
May 11 3.82 3.88
4.00
3.58
67.40K -2.05%
May 10 3.90 3.73
4.02
3.73
23.25K 10.17%
May 9 3.54 3.95
3.99
3.50
73.34K -12.38%